Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus by Timothy A. Gottschalk et al.
October 2015 | Volume 6 | Article 5501
Review
published: 28 October 2015
doi: 10.3389/fimmu.2015.00550
Frontiers in Immunology | www.frontiersin.org
Edited by: 
James Harris, 
Monash University, Australia
Reviewed by: 
Laurence Morel, 
University of Florida, USA 
Matthew Cook, 
Canberra Hospital and Australian 
National University, Australia 
Joanne Reed, 
Garvan Institute, Australia
*Correspondence:
Margaret L. Hibbs 
margaret.hibbs@monash.edu
Specialty section: 
This article was submitted to 
Immunological Tolerance, 
a section of the 
journal Frontiers in Immunology
Received: 27 August 2015
Accepted: 14 October 2015
Published: 28 October 2015
Citation: 
Gottschalk TA, Tsantikos E and 
Hibbs ML (2015) Pathogenic 
inflammation and its therapeutic 
targeting in systemic lupus 
erythematosus. 
Front. Immunol. 6:550. 
doi: 10.3389/fimmu.2015.00550
Pathogenic inflammation and its 
therapeutic targeting in systemic 
lupus erythematosus
Timothy A. Gottschalk , Evelyn Tsantikos and Margaret L. Hibbs*
Leukocyte Signalling Laboratory, Department of Immunology and Pathology, Alfred Medical Research and Education 
Precinct, Monash University, Melbourne, VIC, Australia
Systemic lupus erythematosus (SLE, lupus) is a highly complex and heterogeneous 
autoimmune disease that most often afflicts women in their child-bearing years. It is 
characterized by circulating self-reactive antibodies that deposit in tissues, including 
skin, kidneys, and brain, and the ensuing inflammatory response can lead to irreparable 
tissue damage. Over many years, clinical trials in SLE have focused on agents that con-
trol B- and T-lymphocyte activation, and, with the single exception of an agent known as 
belimumab which targets the B-cell survival factor BAFF, they have been disappointing. 
At present, standard therapy for SLE with mild disease is the agent hydroxychloroquine. 
During disease flares, steroids are often used, while the more severe manifestations 
with major organ involvement warrant potent, broad-spectrum immunosuppression with 
cyclophosphamide or mycophenolate. Current treatments have severe and dose-limit-
ing toxicities and thus a more specific therapy targeting a causative factor or signaling 
pathway would be greatly beneficial in SLE treatment. Moreover, the ability to control 
inflammation alongside B-cell activation may be a superior approach for disease control. 
There has been a recent focus on the innate immune system and associated inflamma-
tion, which has uncovered key players in driving the pathogenesis of SLE. Delineating 
some of these intricate inflammatory mechanisms has been possible with studies using 
spontaneous mouse mutants and genetically engineered mice. These strains, to varying 
degrees, exhibit hallmarks of the human disease and therefore have been utilized to 
model human SLE and to test new drugs. Developing a better understanding of the 
initiation and perpetuation of disease in SLE may uncover suitable novel targets for 
therapeutic intervention. Here, we discuss the involvement of inflammation in SLE dis-
ease pathogenesis, with a focus on several key proinflammatory cytokines and myeloid 
growth factors, and review the known outcomes or the potential for targeting these 
factors in SLE.
Keywords: inflammation, SLe/lupus, nephritis, immunopathology, interleukin-6, proinflammatory cytokines, lupus 
models, therapeutics
Abbreviations: ANAs, antinuclear antibodies; APPs, acute-phase proteins; auto-Abs, autoantibodies; BAFF, B-cell-activating 
factor of the TNF family; CRP, C-reactive protein; IC, immune complex; IFN, interferon; Ig, immunoglobulin; IL, interleukin; 
mAb, monoclonal antibody; SLE, systemic lupus erythematosus/lupus; Th, T helper; TLR, toll-like receptor; Treg, regulatory T cell.
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iNTRODUCTiON
Systemic lupus erythematosus (SLE, lupus) is a B-cell-mediated 
autoimmune disease characterized by the generation of autoan-
tibodies against nuclear antigens and a type III hypersensitivity 
reaction leading to chronic systemic inflammation. The disease 
is polygenic and highly complex, requiring interplay between 
multiple immunopathogenic factors including host autoantigens 
and both cellular and humoral immune components that con-
tribute to the generation of a hyperinflammatory environment 
resulting in organ and tissue damage (Figure  1). Deposition 
of circulating autoantibody–autoantigen complexes can occur 
in various tissues and organs of the body, resulting in a local 
inflammatory response and severe tissue destruction. Sites often 
affected include skin (cutaneous lupus), the nervous system 
(CNS lupus), joints and muscles (rheumatoid lupus, rhupus), 
and the kidney (renal lupus, lupus nephritis), which contributes 
most significantly to disease morbidity (1). Disease progression 
is non-linear and follows a relapse-remitting course, and due 
to its heterogeneous nature, it can vary widely from patient to 
patient, making diagnosis and treatment a challenge (1). The 
current diagnostic criteria require a patient to present with 4 out 
of 11 symptoms/disorders, including cutaneous rashes, inflam-
mation of the pleura or pericardium, inflammation of joints and 
muscles, renal and/or neurologic disorders, hematologic and 
immunologic disorders, and most significantly, autoantibodies 
specifically targeting nuclear antigens (such as double-stranded 
DNA, small nuclear riboproteins, chromatin, and histone pro-
teins), or to a lesser extent, cytoplasmic antigens (2). SLE has a 
strong genetic component with a high familial concordance, but 
environmental triggers such as UV radiation, stress, medication, 
or infection can contribute to disease onset. Genetic analyses, and 
more recently, genome-wide association studies, have uncovered 
various human SLE susceptibility genes that are normally respon-
sible for maintaining immune system tolerance and homeostatic 
processes. These include antigen processing and presentation 
(HLA, TAP1/2), clearance of apoptotic debris (C1q, Dnase1), 
leukocyte cell surface receptors (FCGRI/II/III, ITGAM), and cell 
FiGURe 1 | inflammation is a key factor in the pathogenesis of lupus. A hallmark of lupus is the presence of hyperactive B cells and loss of B-cell tolerance. 
Immune complexes containing nucleic acid autoantigens can engage and activate endosomal TLRs and promote inflammation in SLE. Plasma cell expansion and 
the production of autoantibodies are also features, although the autoantibodies are benign unless generated in an inflammatory milieu, wherein class-switching to 
pathogenic isotypes occurs. Proinflammatory cytokines not only drive T-cell activation and dendritic cell maturation, but they can stimulate extramedullary 
hematopoiesis leading to expansion of innate immune cells, and they can induce the production of acute-phase proteins (APPs). Autoantibodies become deposited 
in tissues such as the glomeruli of the kidney, leading to the activation of myeloid effector cells via Fcγ and complement receptors, leading to tissue destruction. 
Numerous factors, including genetic make-up, environment, diet, and stress, can modify disease course and severity.
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signaling and gene transcription molecules (LYN, BLK, PTPN22, 
STAT4, IRF5) (3, 4). SLE affects approximately one in every 
2,500 individuals, although this can be highly variable based on 
geographical location, ethnicity, and sex [reviewed in Ref. (5, 
6)]; SLE is most commonly seen in females (9:1 prevalence) with 
disease onset typically around child-bearing age and in those of 
non-Caucasian ethnicity.
As SLE is highly complex, multifactorial, and manifests in 
an array of pathologies, the disease has been difficult to study 
in humans. Mouse models that mimic aspects of SLE pathol-
ogy and pathogenesis include the naturally occurring mutants 
MRLlpr/lpr, NZB/W F1, congenic BSXB/Yaa, NZM2410, B6.sle1.
sle2.sle3, B6.sle1.Yaa, transgenic (Tg) overexpression of BAFF 
in BAFF-Tg, and induced models such as pristane and ALD-
DNA [reviewed in Ref. (7, 8)]. One well-studied model of SLE 
is the Lyn-deficient mouse (Lyn−/−) (9), which exhibits clinical, 
pathological, and biochemical features seen in human SLE [com-
prehensively reviewed in Ref. (10)]. Lyn−/− mice develop serum 
antinuclear antibodies (ANAs) and acquire glomerulonephritis 
due to immune complex deposition in kidney (9), which leads 
to renal dysfunction (11). The mice show hematologic disorders 
such as lymphopenia and thrombocytopenia (9) and develop 
splenomegaly and lymphadenopathy (12). Similar to SLE 
patients, Lyn−/− mice also have hyperactive B lymphocytes and 
altered signaling pathways (13–15). Lyn is a haploinsufficiency 
gene in autoimmunity (16), and it is implicated in human disease 
(10). Much of our current understanding of SLE disease patho-
genesis and many preliminary therapeutic studies for SLE have 
come from the identification, analysis, or testing of these mouse 
models [reviewed in Ref. (17, 18)].
inflammation and immunopathology of 
Lupus Nephritis
One or more mechanisms of B-cell tolerance are lost in SLE, 
allowing for the production of ANAs by plasma cells [reviewed 
in Ref. (19, 20)] (Figure 1). Upward of 90% of SLE patients have 
elevated titers of serum ANAs, on average 2–3  years prior to 
clinical onset of SLE (21), with 30–70% of SLE patients develop-
ing life-limiting renal disease (22). The temporal delay between 
autoantibody development and disease onset coupled with 
incomplete penetrance of ANA-mediated disease suggests that 
pathogenesis of autoantibody-driven nephritis is conditional 
upon other factors, such as antigen availability, a pre-established 
inflammatory environment, and T-cell-mediated antibody iso-
type switching (Figure 1). While a hallmark of inflammation is 
the elevation in levels of C-reactive protein (CRP), many lupus 
patients demonstrate normal or even reduced levels of CRP. CRP 
is involved in the clearance of apoptotic cells [reviewed in Ref. 
(23, 24)], and if they are inadequately cleared, this can expose 
nuclear antigens allowing for ANAs to extensively bind and form 
immune complexes (ICs). Such ICs can deposit in the basement 
membrane of the glomerular microvessels (25), resulting in 
activation of the alternative complement pathway and recruit-
ment of proinflammatory macrophages and dendritic cells to the 
glomeruli via chemotactic signaling which upregulate inflamma-
tory cytokine production and activate autoreactive T-cell subsets 
through antigen presentation and costimulation (Figure 1) (22, 
26). Endosomal toll-like receptors (TLR)-7 and TLR-9 in acti-
vated B cells, plasmacytoid dendritic cells, and macrophages can 
respond to internalized self ICs containing nucleic acids, which 
can contribute to the initiation and perpetuation of the inflam-
matory cascade (Figure 1) [reviewed in Ref. (27)]. CD4+ T helper 
cells play several key roles in the pathogenesis of lupus nephritis: 
T helper 1 (Th1) cells are responsible for high-level production 
of proinflammatory cytokines, such as interferon-γ (IFN-γ), 
which stimulates dendritic cell and myeloid cell production of 
interleukin-(IL)-1, IL-6, IL-12, IL-18, TNF-α, and BAFF creating 
a perpetual proinflammatory loop; T helper 2 cells (Th2) produce 
cytokines (IL-4, IL-5), which induce antibody isotype class-
switching leading to the production of high affinity, pathogenic 
autoantibodies [reviewed in Ref. (28, 29)]; Th17 cells also provide 
B-cell support, promote plasma cell differentiation and patho-
genic autoantibody production and myeloid cell hyper-activation 
which drives systemic inflammation (30, 31); T follicular helper 
cells (TFH) are now also known to contribute to autoimmune 
germinal center reactions or autoantibody production in lupus-
prone mice and SLE patients (32, 33) [reviewed in Ref. (34)]. 
Aside from autoantibody production (Figure 2A), autoreactive 
B cells contribute to the pathogenesis of lupus nephritis via two 
supportive mechanisms: B cells can activate autoreactive T cells 
through antigen presentation and costimulation (Figure 2B) and 
they can produce cytokines including IL-6, a proinflammatory 
cytokine able to drive inflammation and inhibit the generation 
of autoimmune suppressive regulatory T cells (Treg) (Figure 2C) 
(22, 29). As well as T-cell-induced antibody isotype switching 
within germinal centers, evidence shows ectopic germinal center-
like congregations within the glomeruli of SLE patients suggesting 
B cells may undergo local somatic hypermutation of immuno-
globulin (Ig) variable region genes generating both higher affin-
ity autoantibodies and memory B cells (35). Inflammation and 
cytotoxicity caused by the immune response generated against 
glomerular ICs results in progressive renal tissue damage includ-
ing immune cellular influx and progressive fibrotic, sclerotic, and 
necrotic lesions (36). As a consequence of this, patients suffer glo-
merular degeneration and reduced kidney function, which may 
result in end-stage renal failure requiring dialysis or transplanta-
tion (37). Currently, there is an incomplete understanding of the 
factors driving pathogenesis in lupus nephritis, which hinders the 
development of novel, targeted therapeutics.
Current Treatments and Lack of Clinical 
Success of B-Cell-Directed Therapies
Treatment of SLE has remained fairly consistent over the past 
50  years utilizing non-specific anti-inflammatory agents such 
as non-steroidal anti-inflammatory drugs and the immune cell 
modulating hydroxychloroquine for mild disease, and broad-
spectrum immunosuppressants/anti-inflammatories such as 
corticosteroids, azathioprine, cyclophosphamide, or mycophe-
nolate during flares or severe disease with organ involvement 
(38). These therapies can have severe, dose-limiting toxicities 
and undesirable side effects, and some patients lack an adequate 
response, highlighting the need for a treatment regime tailored to 
FiGURe 2 | The roles of B cells in lupus pathogenesis. B cells have 
multiple roles in autoimmunity through (A) their ability to produce 
autoantibodies and (B) via their role as antigen-presenting cells and (C) as 
producers of inflammatory cytokines.
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individual patients (38). Development and trial of novel targeted 
treatments for SLE have been difficult due to the complexity and 
limited knowledge of disease etiology, loose diagnostic criteria, 
various disease manifestations, and the diverse heterogeneity of 
patients [reviewed in Ref. (39)].
Despite promising results in animal models (40), therapeutic 
targeting of B cells in SLE has had minimal success, especially in 
patients with lupus nephritis. B-cell depletion using rituximab, a 
monoclonal antibody targeting the B-cell-specific receptor CD20 
(anti-CD20 mAb), was unsuccessful at meeting primary and sec-
ondary endpoints in stage II/III SLE clinical trials despite showing 
initial promising results (41, 42). Ocrelizumab, a humanized anti-
CD20 mAb, also failed in phase III clinical trials demonstrating 
insignificant renal improvement and increases in severe infection 
of patients (43). Inhibition of B-cell survival pathways by neu-
tralizing the survival receptor TACI, using a humanized fusion 
protein atacicept, was initially deemed safe in phase I trials but 
efficacy has not been determined due to safety concerns during 
a phase II/III trial which led to its premature termination (44). 
Modulation of B-cell receptor signaling using epratuzumab (anti-
CD22 mAb) has yielded some promising results in non-renal 
SLE patients although there is currently no data on outcomes in 
patients with lupus nephritis (45). Recombinant small-molecule 
inhibitor abatacept, which blocks T-cell co-stimulatory ligands 
(CD80 and CD86) on B cells and dendritic cells, also failed to 
meet primary and secondary endpoints in a phase II clinical trial 
of SLE patients which largely excluded lupus nephritis patients 
(46).
Despite this lack of success, belimumab, a monoclonal antibody 
that neutralizes the soluble B-cell activation and survival factor 
BAFF, has recently been approved for SLE patients with active dis-
ease in the USA and Europe by the Federal Drug Administration 
(FDA) and the European Medicines Agency after successful 
phase III clinical trials showing modest improvements in disease 
(47, 48). It is now also available for use in other countries, such 
as Australia. Belimumab is not only the first targeted therapeutic 
indicated for SLE but also the first new therapeutic approved 
for SLE in over 50  years. However, the benefits obtained with 
belimumab are modest and only attained in patients with mild 
disease who are already receiving standard therapy (47). Given 
the overall lack of success of lymphocyte-targeted therapeutics, 
coupled with the heterogeneity and diverse array of clinical mani-
festations of disease and the contribution of inflammatory factors 
to disease development in SLE, more consideration to non-B-cell 
targets and combination therapeutic regimes are required in 
order to deliver a more personalized and effective approach to 
treating SLE. The focus of this review will be to discuss the cur-
rent understanding of proinflammatory cytokines and myeloid 
growth and activation factors as well as the promising outcomes 
and potential for the therapeutic targeting of these factors in SLE.
TARGeTiNG iNFLAMMATiON iN LUPUS
Myeloid-Derived inflammatory Factors in 
Lupus Pathogenesis and Targeted 
Treatment
Interleukin-1 and the Inflammasome
The inflammasome is a complex that responds to “danger sig-
nals” and induces the cleavage and release of bioactive IL-1, a 
cytokine upstream of many proinflammatory responses (49). 
The importance of inflammasome activation and the induction 
of IL-1 have been elucidated by several studies and have drawn an 
important link between the innate immune system and autoim-
munity  (50,  51). Increased IL-1 gene expression was observed 
in MRLlpr/lpr mice (52, 53), and inhibition of the NLRP3 inflam-
masome/IL-1β axis in MRLlpr/lpr mice attenuated proteinuria, 
autoantibody production, systemic proinflammatory cytokines, 
and kidney pathology (54, 55). When SLE was induced in mice 
deficient in IL-1, they showed reduced levels of autoantibody and 
milder disease manifestations (56). It was also found that IL-1 
induced IgG production by cells from SLE patients and healthy 
controls (57), and increased IL-1 levels were produced by B cells 
from SLE patients (58) and were found in the cerebrospinal 
fluid (CSF) of patients with neural SLE (59). A single-nucleotide 
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polymorphism in the IL1B gene (rs1143629) is associated with 
juvenile-onset SLE, implicating IL-1β in the early stages of SLE 
pathogenesis (60). Treatment of MRLlpr/lpr and NZB/W F1 mice 
with anti-IL-1R antibody reduced autoantibody titers (61, 62). 
A preliminary study treating patients with the IL-1R antagonist 
anakinra showed promising results (63); however, no further 
studies have since been published.
In contrast with the concept of a critical role for inflammasome 
activation in autoimmunity, inflammasome deficiency due to a 
point mutation in the NLRP3 gene has recently been identified 
in lupus-prone NZB/W F1 mice correlating with reduced IL-1β 
release (64). In addition, the NLRP3/ASC inflammasome pro-
tected against kidney damage independent of IL-1 signaling due 
to regulation of the anti-inflammatory activity of transforming 
growth factor-β (TGF-β) in C57BL6/Jlpr/lpr mice, which represent a 
mild spontaneous model of lupus (65). Collectively, these studies 
suggest that therapeutic targeting of the inflammasome in SLE 
may exacerbate disease in some patients or only be suitable for 
patients with a certain inflammatory profile. Recently, emphasis 
has been placed on understanding how the inflammasome 
contributes to proinflammatory cell death (pyroptosis) and 
the subsequent modification of autoantigens and generation of 
autoimmune responses in lupus (66).
Interferon Alpha
Interferon alpha (IFN-α) is one of the most strongly implicated 
cytokines in the pathogenesis of SLE (67). Early studies showed 
that IFN-α was increased in the serum and found to be associ-
ated with increased disease activity (68–71). Correlations were 
also found between the levels of IFN-α and IC in the serum 
(69) as well as the deposition of IC in kidney sections from SLE 
patients (72). This may be due to IFN-α having an antagonistic 
effect on CRP production, leading to the elevation of available 
nuclear antigens (23). In addition, IFN-α was expressed at high 
levels in the CSF of patients with neural lupus (73, 74), and CSF 
from these patients had strong IFN-α-inducing ability when 
added to cell cultures (75). Treatment of a patient harboring a 
malignant tumor with IFN-α induced SLE-like symptoms (76), 
and it is also epidemiologically interesting that SLE patients with 
high IFN-α levels showed low rates of hepatitis B infections (77), 
highlighting the role of IFN-α not only in antitumor and antivi-
ral responses but also in the pathogenesis of SLE. Interestingly, 
viral DNA and RNA as well as self nucleic acid-containing ICs 
stimulate IFN-α production by plasmacytoid dendritic cells 
via TLR-7 and TLR-9; specific inhibitors toward these TLRs 
potently inhibited IFN-α production (78), and treatment of 
lupus-prone NZB/W F1 mice with these inhibitors significantly 
reduced serum ANAs, glomerulonephritis, and organ damage 
while improving survival (79). In addition, increased TLR-7 and 
TLR-9 expression in PBMCs from SLE patients was correlated 
strongly with high levels of IFN-α mRNA (80), thus bridging 
innate immunity with autoimmunity. Clinical assessment of 
targeting IFN-α has shown safety (81). A phase II study did not 
reach its primary endpoint; however, exploratory analysis of the 
results did reveal positive reductions in disease (82). A phase 
I/II trial in SLE patients examining the safety of IFNα kinoid 
(IFN-K) that induces a host polyclonal antibody response to 
IFN-α is currently underway (NCT01058343). A phase I trial in 
lupus patients testing sifalimumab (MEDI-545), a human anti-
IFN-α mAb, showed safety, tolerability, and clinical activity (83), 
which has led to a phase IIb trial, which has now been completed 
although no data have been published (NCT00299819). Studies 
targeting TLRs in nephritic SLE are currently lacking; however, 
small-molecule TLR antagonists are starting to be assessed for 
efficacy in animal models (84). Very interestingly, it is now 
apparent that hydroxychloroquine, a mainstay in lupus treat-
ment, is a TLR-7 and TLR-9 antagonist. Thus, manipulation of 
TLR signaling with new agents promises to be a future growth 
area in the clinical management of inflammatory and autoim-
mune diseases such as SLE [reviewed in Ref. (85)].
Interferon Gamma
Interferon gamma (IFN-γ) is a prototypic Th1 cytokine that 
activates a proinflammatory program in macrophages. Like IFN-
α, IFN-γ is also elevated in the serum of SLE patients (86–88). 
Increased IFN-γ levels were also found in lymphoid organs of 
prediseased MRLlpr/lpr mice (52) while increased IFN-γ-producing 
T cells were correlated with autoantibody titers and proteinuria 
in aged diseased mice (89). Treatment of NZB/W F1 mice with 
IFN-γ accelerated disease while neutralization of IFN-γ resulted 
in reduced disease symptoms and improved survival (90, 91); 
furthermore, genetic deletion of IFN-γ receptor in these mice 
impaired autoantibody production and glomerulonephritis (92). 
Studies in the Lyn−/− mouse model showed that genetic deletion 
of IFN-γ led to reduced production of BAFF and decreased 
myeloid proliferation and T-cell hyperactivation, thereby result-
ing in moderation of glomerular disease (93). Analysis of PBMCs 
from SLE patients showed that they had significantly higher IFN-
γ transcripts compared to control PBMCs (94) and that T cells 
from SLE patients produced more IFN-γ, which induced BAFF 
production by monocytes (95), while SLE NK cells produced 
higher IFN-γ (96). There are currently no completed trials on 
the effect of neutralizing IFN-γ in SLE patients (97); however, a 
recent single-dose study treating SLE patients with AMG811, an 
anti-INF-γ IgG1 mAb, was well tolerated and showed reductions 
in IFN-γ-mediated gene expression (98).
Tumor Necrosis Factor Alpha
Tumor necrosis factor alpha (TNF-α) is an interesting and 
controversial cytokine in the field of SLE due to its apparent 
dual role (99). Similar to other proinflammatory cytokines, 
increased levels of TNF-α have been observed in the serum 
of lupus-prone animals and SLE patients (100). In particular, 
elevated serum levels and gene expression levels are positively 
associated with disease activity as well as renal involvement in 
SLE patients (88, 101). While TNF-α blockade has been suc-
cessful as a mainstay treatment for rheumatoid arthritis (102), 
the assessment of this therapy in SLE patients has not been 
straightforward. In SLE patient studies, anti-TNF-α therapy 
increases the serum levels of anti-dsDNA and antiphospholipid 
autoantibodies (103). It would follow that a further increase 
in antiphospholipid antibodies in patients may lead to vas-
cular events, which although rare, have the potential to be 
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life-threatening. In addition, the risk of bacterial infection is 
increased as a result of anti-TNF-α therapy (104). Despite the 
risks, treatment has led to syndromes that are transient, mild 
in nature, have not induced flares, and have resulted in reduc-
tions in proteinuria and provided benefit to patients with lupus 
arthritis (105). A more recent study has demonstrated safety 
and efficacy of anti-TNF-α therapy in SLE (106). It is suggestive 
that any consideration of anti-TNF-α for the treatment of SLE 
patients must be for a short duration only and not recom-
mended for patients with antiphospholipid syndrome [up to 
15% of SLE patients (107, 108)]. It is still debatable whether the 
risks associated with therapeutic targeting of TNF-α in SLE are 
worth the benefits obtained.
B-Cell-Activating Factor of the TNF Family
B-cell-activating factor (BAFF) is an important B-cell survival 
factor with well-known pathogenic roles in SLE. It is expressed 
by numerous cells in the immune system but is highly expressed 
by innate immune cells. Mice engineered to overexpress BAFF 
developed autoimmune manifestations (109) while overexpres-
sion of BAFF in lupus-prone congenic strains accelerated renal 
pathology (110). BAFF levels are increased in the serum of 
patients with SLE (111, 112) and are associated with increased 
anti-dsDNA antibody levels (113) and disease activity (114, 115). 
Neutralization of BAFF in lupus-prone NZB/W F1 mice depleted 
B cells, prevented progressive T-cell activation and dendritic cell 
accumulation, and prolonged survival (116). Lyn−/− mice show 
excessive BAFF production by myeloid cells and treatment with 
anti-BAFF mAb attenuated their lupus-like disease (93). BAFF 
neutralization also reduced glomerulonephritis and improved 
survival in lupus-prone BXSB/Yaa mice (117) and NZM2410 mice 
(118). T cells from SLE patients produced large amounts of BAFF 
in culture (119) and had significantly upregulated BAFF mRNA 
(120) compared to control T cells. Increased BAFF expression 
was also found in SLE B cells and was positively associated with 
anti-dsDNA autoantibody and disease activity scores (121), indi-
cating that as well as being produced by other cell types, B cells 
from SLE patients can produce BAFF in an autocrine manner. 
Especially pertinent is the FDA approval of belimumab (trade 
name Benlysta®), a neutralizing antibody against BAFF, for the 
treatment of SLE (48), spurred by the success of a randomized 
double-blind placebo-controlled trial that demonstrated efficacy 
and safety in SLE patients treated with belimumab over placebo 
(47). This pathway continues to dominate the focus of SLE clini-
cal trials.
Myeloid Growth Factors Drive 
Splenomegaly, inflammatory Myeloid 
Phenotypes, and Contribute to the 
immunopathology of Lupus Nephritis
Extramedullary hematopoiesis is often a hallmark of infectious 
and inflammatory diseases, driven by excess production of 
myeloid growth factors and is evident in models of lupus such 
as Lyn−/−, NZB/W F1, and MRLlpr/lpr mice (Figure 1) (15, 122). 
This phenomenon may contribute to the splenomegaly seen 
in some lupus patients and lupus-prone mice (15, 122, 123). 
Myeloid growth factors stimulate progenitor cell release from 
bone marrow, myeloid cell production, and cellular activation, 
and this may promote enhanced inflammatory responses and 
tissue damage depending on tissue context. Several studies 
have implicated myeloid growth factors, including IL-3, 
M-CSF, and GM-CSF, in the inflammatory pathways and 
pathology in SLE.
Interleukin-3
Interleukin-3 (IL-3) is a pleiotropic, synergistic growth fac-
tor that is involved in the differentiation, activation, and 
support processes of many immune cells including dendritic 
cells (124). Although it has long been known that IL-3 can be 
elevated in SLE patients (125), very few studies on the role of 
IL-3 in SLE have since been conducted. In the Lyn-deficient 
mouse model of lupus, IL-3-responsive progenitor cells are 
elevated in spleen (15), and IL-3 induces enhanced signaling 
and survival of Lyn−/− plasma cells, suggesting it may play a 
role in the support of autoreactive plasma cells (126). Recently, 
a study has shown that IL-3 can drive glomerulonephritis in 
MRLlpr/lpr mice, hypothesized to be due to enhanced antigen 
presentation by dendritic cells, elevated Ig secretion, and/
or basophil-mediated support functions (127). Treatment of 
MRLlpr/lpr mice with an anti-IL-3 mAb ameliorated nephritis, 
improved kidney function, and restrained production of certain 
autoantibodies (127). This suggests that the IL-3 axis might be 
an undervalued contributor to inflammation and pathology in 
SLE, and future studies to further our understanding of this 
system may benefit the development of superior treatment 
regimes.
Macrophage Colony-Stimulating Factor
Macrophage colony-stimulating factor (M-CSF) is a myeloid 
growth factor that induces the differentiation of myeloid precur-
sor cells into monocytes/macrophages or dendritic cells as well as 
regulating macrophage functions, survival, trafficking, and pro-
liferation, and it is associated with inflammatory pathology (128). 
M-CSF is elevated in the serum of SLE patients and correlates 
with active disease, renal pathology, and myeloid activation syn-
drome (129, 130). Local M-CSF production by renal mesangial 
cells is elevated in lupus nephritis and contributes to proteinuria, 
local macrophage infiltration and proliferation, and glomerular 
proliferation (131, 132). M-CSF is also detectable in the urine of 
lupus nephritis patients with levels correlating with flares in renal 
disease (133). Elevated M-CSF is also observed in MRLlpr/lpr mice 
systemically as well as in the kidney (134) and is heavily impli-
cated in driving autoantibody production, glomerular infiltration 
of myeloid cells and nephritis (135). M-CSF is involved in driving 
a proinflammatory, immunopathogenic phenotype in MRLlpr/lpr 
macrophages (136), and in Lyn−/− mice, hematopoietic progeni-
tors responsive to M-CSF are enhanced in spleen (15). Inhibition 
of M-CSF signaling with a selective M-CSF receptor kinase 
inhibitor (GW2580) prevents macrophage and T-cell accumula-
tion in the kidney, restricts the local renal inflammatory profile, 
and improves kidney pathology in an induced model of lupus 
nephritis (137). This highlights that the M-CSF pathway may be 
a novel target for therapeutic trials in SLE.
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Granulocyte–Macrophage Colony-Stimulating Factor
Granulocyte–macrophage colony-stimulating factor (GM-CSF) 
is a growth factor that drives differentiation of myeloid lineage 
cells (granulocytes and monocyte/macrophages), and it can act 
on mature immune cells to upregulate an inflammatory phe-
notype and enhance antigen presentation and migration (138). 
Although there is conflicting evidence as to whether GM-CSF 
levels are altered in SLE (139, 140), the frequency of systemic 
GM-CSF-secreting immune cells is elevated and correlates with 
anti-dsDNA titers in SLE (141). It has also been suggested that 
high concentrations of GM-CSF can drive Ig secretion and 
leukocyte activation marker CD69 expression in lupus patients 
(142). GM-CSF can also be produced locally by glomerular 
mesangial cells and levels correlate with lupus nephritis (131). 
Interestingly, some studies suggest that neutrophils and dendritic 
cells may demonstrate resistance to GM-CSF responses in SLE 
(143, 144). Colony formation by splenic progenitor cells induced 
by GM-CSF is increased in Lyn−/− mice (15). Therapeutic target-
ing of the GM-CSF axis is not currently being explored in SLE, 
but has shown promise in rheumatoid arthritis (138). MOR103, 
a humanized anti-GM-CSF mAb, has recently successfully com-
pleted a phase I/II trial in rheumatoid arthritis reporting safety 
and preliminary efficacy (145), and a fully human anti-GM-CSF 
receptor mAb, mavrilimumab, is currently in phase II trial 
(NCT01712399). Further studies delineating the role of GM-CSF 
in inflammation and pathology in SLE may highlight this system 
as a potential target for treatment in a subset of SLE patients.
interleukin-6: a Major Mediator of 
inflammation in SLe
IL-6 Drives Immunopathology in Lupus Nephritis
Interleukin-6 (IL-6) is a pleiotropic cytokine that acts on a range 
of cell types; it can influence growth and differentiation and 
antibody production and mediates the acute-phase inflammatory 
response. It is also highly implicated in the pathogenesis of many 
inflammatory and autoimmune diseases [reviewed in Ref. (146)]. 
IL-6 has consistently been shown to be elevated in the serum of 
SLE patients and it has been suggested that levels correlate with 
disease activity, making it a suitable biomarker for tracking 
disease activity (147–150). Similarly, IL-6 can be elevated in the 
urine of lupus nephritis patients, with higher levels correlating 
with active renal inflammation and pathology (151, 152). IL-6 
has been implicated in driving autoantibody production and loss 
of tolerance in SLE through the upregulation of recombination-
activating gene (RAG) activity (153). Studies have identified 
polymorphisms in the IL-6 gene, which are associated with SLE 
susceptibility (154). In mice, elevated levels of IL-6 are observed 
in numerous models, including NZB/W F1 (155), MRLlpr/lpr (156), 
Lyn−/− (15), ALD-DNA (157), B6.sle1.sle2.sle3 (158), and B6.sle1.
Yaa (159), and it is heavily implicated in pathology. Studies in 
IL-6-deficient mice have shown that they are resistant to ALD-
DNA-induced lupus, which ordinarily promotes anti-dsDNA 
autoantibody titers, proteinuria, CD4+ T-cell activation, and 
glomerulonephritis (157). The mechanism is thought to be due 
to an expansion of regulatory T cells in the absence of IL-6, which 
ordinarily suppresses their generation (157). Impaired Treg matu-
ration and activity was observed in B6.sle1.sle2.sle3 mice due to 
overproduction of IL-6 by dendritic cells (158). IL-6 has also been 
shown to promote disease in Lyn−/− mice as Lyn−/−IL-6−/− show 
moderated B-cell hyperactivity and plasmacytosis and abrogation 
of T-cell hyperactivity and splenic myeloid cell expansion (15). In 
addition, class-switched pathogenic ANAs, glomerular IgG, and 
complement deposition are absent in Lyn−/−IL-6−/− mice, and 
glomerular structural integrity is significantly improved (15). 
Similarly, IL-6-deficient MRLlpr/lpr mice showed greatly improved 
survival with significant amelioration of renal immunopathol-
ogy (160), and in B6.Sle1.Yaa mice, IL-6 deficiency eliminated 
autoantibody production and nephritis (161).
It has been hypothesized that classic IL-6 signaling via 
membrane-bound IL-6R (Figures 3A,B) does not contribute to 
chronic inflammation but mediates regulated pathogen clear-
ing processes through anti-inflammatory pathways. However, 
IL-6 trans-signaling through soluble IL-6R/gp130 complexes 
(Figure  3C) is believed to be associated with chronic inflam-
matory conditions by driving hyperinflammatory and immu-
nopathogenic processes (162). Specific downregulation of IL-6 
trans-signaling in Lyn−/− mice through transgenic overexpression 
of soluble gp130-Fc fusion protein (Lyn−/−sgp130FcTg) resulted 
in a loss of splenomegaly, a decrease in splenic myeloid cells, and 
reduced systemic BAFF levels (163). Although pathogenic ANA 
production was sustained, as was IgG IC deposition in kidney glo-
meruli, renal complement deposition was significantly reduced, 
which suppressed renal leukocyte infiltration, thereby markedly 
attenuating glomerulonephritis and improving kidney function 
(163). These findings suggest that more emphasis should be put on 
examining the role of IL-6-trans-signaling in lupus nephritis, with 
the possibility of targeting this inflammatory pathway in disease.
Targeting IL-6 has Therapeutic Potential
There is much evidence to suggest that IL-6 plays a significant 
role in a number of inflammatory, autoimmune, and proliferative 
diseases, making it a strong candidate for targeted novel biologi-
cal therapeutics [reviewed in Ref. (164)]. This notion is further 
enhanced by the improvement seen in IL-6-targeted murine 
SLE models. A preliminary study treating NZB/NZW F1 mice 
monthly with anti-IL-6 in combination with anti-IL-1α concluded 
that this regime only had a partial effect on disease, alleviating 
proteinuria (165). Young NZB/NZW F1 mice treated weekly with 
a rat anti-IL-6 monoclonal antibody from 3 to 9 months of age 
showed reduced ANA production, improved proteinuria, and 
increased survival, although these mice required initial toler-
izing treatments of anti-CD4 to prevent a rapid-onset anti-rat Ig 
response (166). A more thorough study in young NZB/W F1 mice 
without anti-CD4 tolerance showed that anti-IL-6 mAb treatment 
suppressed systemic serum amyloid A (SAA) and anti-dsDNA 
antibody levels, suppressed hyperactivation of B and T cells, and 
greatly diminished the development of kidney pathology (167).
The use of murine IL-6 targeting monoclonal antibodies in 
human disease has been unsuccessful as IL-6/mAb immune com-
plexes form which can further drive pathology in inflammatory 
settings (168). A fully humanized anti-IL6 mAb, sirukumab, has 
shown tolerance in humans (169, 170) and efficacy in treating 
rheumatoid arthritis (171). A phase I trial in cutaneous and sys-
temic lupus patients (NCT01702740) concluded that sirukumab 
October 2015 | Volume 6 | Article 5508
Gottschalk et al. Targeting pathogenic inflammation in lupus
Frontiers in Immunology | www.frontiersin.org
is generally well tolerated in SLE although mild leukopenia, 
neutropenia, and decreases in platelet count were observed (172). 
A phase II trial in lupus nephritis patients (NCT01273389) has 
recently been completed with official outcomes not yet reported, 
although unofficial accounts indicate a high frequency of serious 
adverse events, the majority of which were infections.
A study examined the effect of targeting IL-6R in MRLlpr/lpr 
mice by treating 15-week-old animals every 1–3 days for 5 weeks 
with a neutralizing rat anti-IL-6R mAb. These mice saw an initial 
reduction in anti-dsDNA autoantibodies, which rebounded and 
elevated in response to increasing titers of anti-rat Ig antibodies 
(173). The treatment was reported as successful as both kidney 
function and structure was improved at the endpoint compared 
to controls (173). Tocilizumab, a humanized murine anti-IL6-R 
mAb, has demonstrated efficacy in treating multiple myeloma 
(174) and rheumatoid arthritis (175). A phase I safety trial 
demonstrated that tocilizumab is well tolerated in SLE patients 
although similarly to sirukumab, temporary dose-dependent 
neutropenia was observed (176). A recent study in SLE patients 
showed that tocilizumab treatment can reduce B- and T-cell 
activation, memory B cells, and autoantibody-producing plasma 
cells without impacting naive B cells populations (177).
Given that anti-IL-6 and anti-IL6R inhibition may lead to 
unwanted neutropenia and infection, targeting IL-6 trans- 
signaling without disrupting classical signaling pathways may 
prove to be a superior approach in SLE as many anti-inflammatory 
and regulatory mechanisms mediated by IL-6 classic signaling 
will not be impacted (Figure 3D) (162, 163, 178). A fusion protein 
joining sgp130 to the IgG Fc region, sgp130Fc, has demonstrated 
effective inhibition of soluble IL-6R-mediated trans-signaling 
FiGURe 3 | Duplicitous signaling roles of iL-6. (A) Classical IL-6 signaling occurs via direct interaction of IL-6 with the membrane-bound IL-6 receptor, which 
has a limited cellular distribution, and the ubiquitously expressed gp130. gp130 lacks intrinsic kinase activity; IL-6 signals are transduced intracellularly via the 
recruitment and activation of the JAK/STAT pathway. (B) Cells lacking the IL-6 receptor are not receptive to IL-6 except (C) in the presence of the IL-6/soluble IL-6 
receptor complex which interacts with gp130 expressing cells and this is defined as IL-6 trans-signaling. (D) Inhibition of IL-6 trans-signaling can be achieved via the 
presence of excess soluble gp130Fc fusion protein.
(178). Proof of concept for sgp130Fc treatment has been dem-
onstrated in a range of inflammatory disease models, including 
rheumatoid arthritis (179, 180), atherosclerosis (181), and Crohn’s 
disease (178). Given its efficacy, it is surprising that no clinical 
trials utilizing this agent in lupus appear to be in the pipeline.
Components of signaling pathways that are aberrantly 
activated in disease are attractive drug targets. The JAK/STAT 
signaling pathway is activated downstream of IL-6 and gp130 
(Figures  3A,C) and can be targeted by small-molecule inhibi-
tors, which have already shown promise in cancer therapy (182). 
However, there are few studies on JAK/STAT inhibitor treatments 
in inflammatory diseases; one study demonstrated clinical efficacy 
of the JAK1/2 inhibitor AZD1480 in five models of experimental 
autoimmune encephalitis (EAE, modeling human multiple scle-
rosis) by inhibiting myeloid cell hyperactivation, Th1 and Th17 
differentiation, and proinflammatory cytokine production as 
well as showing improvements in disease and clinical pathology 
(183). A signaling study in Lyn−/− mice showed that treatment 
with AZD1480 resulted in reduced splenic B cells and plasma 
cells as well as reduced numbers of splenocytes and thymocytes; 
however, effects on lupus pathology were not reported (126). 
Although this may be an attractive approach, inhibition of the 
JAK/STAT pathway in autoimmune disease should be under-
taken cautiously and the use of single-specificity inhibitors may 
be more beneficial. Indeed, treatment using the JAK2-selective 
inhibitor CEP-33779 in both NZB/W F1 and MRLlpr/lpr mice 
saw dose-dependent improvements in lymphadenopathy and 
splenomegaly, reductions in systemic C3 and proinflammatory 
cytokines, including IL-1, IL-12, IFN-α, IL-17A, and TNF-α, 
reductions in autoantibody-producing plasma cells, increased 
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survival, and significant improvements in glomerulonephritis 
through blockade of STAT3-mediated signaling (184, 185). These 
animal data lend support for trailing a JAK2 inhibitor in human 
disease. Interestingly, GSK recently halted development of the 
JAK1 inhibitor GSK2586184 following disappointing results in a 
phase II study in SLE (186).
FUTURe DiReCTiONS
Targeting Multiple Aberrant Pathways with 
Combination Therapies
Although the pathogenic pathways involved in SLE are still being 
defined, it is evident that a combination of deregulated processes 
are necessary for the disease to manifest. As pathogenesis in SLE 
is clearly multifactorial, the targeting of a single pathway or fac-
tor may not sufficiently alter the progression of disease. Indeed, 
current treatment utilizes both agents that suppress the immune 
response alongside those that dampen inflammation (38). One of 
the reasons that B-cell-targeted therapies have been largely unsuc-
cessful in SLE trials is that they fail to target pathogenic long-lived 
plasma cells and memory B cells (187). Recent studies in NZB/W 
F1 mice treated with a B cell targeting anti-CD20 mAb alongside 
a plasma cell-depleting agent (188) or BAFF-blocking agent (189) 
resulted in superior improvements in disease compared to B-cell 
depletion on its own. Similarly, depletion of memory B cells 
using an anti-IL-15 mAb alongside TACI-Ig, a soluble form of 
the TACI receptor that binds to BAFF and APRIL ligands, was 
more efficacious than TACI-Ig alone (190). This illustrates that 
combining targeted therapeutics can give rise to better outcomes. 
As systemic inflammation is essential for disease propagation and 
sustenance, controlling both the proinflammatory arm alongside 
pathogenic plasma or memory B-cell depletion may prove to be a 
superior therapeutic approach to disease control in SLE.
CONCLUSiON
Systemic lupus erythematosus is a highly complex autoimmune 
disease with multiple immunopathological disorders, the most 
significant being glomerulonephritis mediated by immune com-
plex deposition in the kidney microvessels. Although autoreactive 
B cells are essential, disease progression relies on the establish-
ment of a systemic inflammatory environment largely generated 
by myeloid cells and T lymphocytes. Current treatment utilizes 
broad-spectrum immunosuppressive and anti-inflammatory 
agents which have many off-target effects. Therapeutic targeting 
of the B-cell compartment in SLE has only had limited success, 
and a need for novel targeted therapeutics is essential for per-
sonalized, effective control of disease to improve quality of life. 
Many therapeutics targeting inflammatory cytokines, growth 
factors, and signaling pathways have shown safety and efficacy 
in inflammatory disorders, and preliminary studies in animal 
models of murine lupus and human lupus nephritis patients 
have demonstrated some promising disease-suppressing effects. 
Presently, there are no therapies for human SLE in clinical prac-
tice that target specific inflammatory pathways and thus further 
studies elucidating the mediators and their mode of action in 
generating the pathogenic inflammatory environment in lupus 
will greatly benefit the selection and development of therapeutics 
for future clinical trials.
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